中医辨证联合美托洛尔治疗冠心病心力衰竭的疗效
|
摘要
目的:观察中医辨证联合美托洛尔治疗冠心病心力衰竭的临床疗效。方法:选取我院收治的冠心病心力衰竭患者80例,按随机数字表法分为对照组和观察组,各40例。对照组仅给予美托洛尔治疗,观察组给予中医辨证联合美托洛尔治疗,比较其临床疗效。结果:经治疗后观察组的总有效率为95.00%(38/40),对照组的总有效率为77.50%(31/40);观察组患者的治疗总有效率显著高于对照组(P <0.05)。观察组患者的不良反应发生率为4例(10.00%),对照组患者的不良反应发生率为10例(25.00%),P <0.05。对照组患者最大耗氧量为(10.15±5.11)mL/(kg·min)、无氧阈为(8.71±3.22)mL/(kg·min)以及心脏指数峰值为(4.02±2.34)mL/(min·m~2)均低于观察组患者的最大耗氧量(20.16±8.97)mL/(kg·min)、无氧阈(15.67±6.94)m L/(kg·min)以及心脏指数峰值(9.67±4.98)mL/(min·m~2),P <0.05。结论:中医辨证联合美托洛尔治疗冠心病心力衰竭疗效显著,可有效改善患者心功能,安全性高。
Objective: To observe the clinical efficacy of TCM syndrome differentiation plus metoprolol on heart failure from coronary heart disease. Methods: 80 patients admitted in our hospital were divided into the control group and the observation group according to the random number table, 40 cases in each. The control group received only metoprolol, and the observation group received TCM syndrome differentiation plus metoprolol. Results: After treatment, the total effective rate in the observation group was 95.00%(38/40),higher than 77.50%(31/40) in the control group. The total therapeutic efficiency in the observation group was significantly higher than that in the control group(P<0.05). The incidence of adverse reactions was 10.00%(4/40) in the observation group, lower than 25.00%(10/40) in the control group(P<0.05). The clinical indexes in the observation group were better than those in the control group(P<0.05). Conclusion:TCM syndrome differentiation plus metoprolol on heart failure from coronary heart disease is effective and safe, can effectively improve the cardiac function of patients.
Objective: To observe the clinical efficacy of TCM syndrome differentiation plus metoprolol on heart failure from coronary heart disease. Methods: 80 patients admitted in our hospital were divided into the control group and the observation group according to the random number table, 40 cases in each. The control group received only metoprolol, and the observation group received TCM syndrome differentiation plus metoprolol. Results: After treatment, the total effective rate in the observation group was 95.00%(38/40),higher than 77.50%(31/40) in the control group. The total therapeutic efficiency in the observation group was significantly higher than that in the control group(P<0.05). The incidence of adverse reactions was 10.00%(4/40) in the observation group, lower than 25.00%(10/40) in the control group(P<0.05). The clinical indexes in the observation group were better than those in the control group(P<0.05). Conclusion:TCM syndrome differentiation plus metoprolol on heart failure from coronary heart disease is effective and safe, can effectively improve the cardiac function of patients.
引文
[1]石锐,孟文宜,王国强,等.痰瘀伏邪与冠心病心力衰竭心功能分级、N端前脑钠素及心脏超声指标相关性研究[J].中国中医急症,2017,26(05):779-782.
[2]王文林,吴敏,赵艳花,等.两种中药注射剂辅助治疗冠心病心力衰竭的成本-效果分析[J].中国药房,2015,26(26):3614-3616.
[3]顾丽萍,胡菁,严蜀华.美托洛尔与曲美他嗪治疗老年冠心病心力衰竭的疗效及对患者心功能、心肌重塑和炎症因子的影响[J].中国老年学杂志,2017,37(01):89-91.
[4]黄孟军.中医辨证联合美托洛尔治疗冠心病心力衰竭的临床疗效分析[J].中医临床研究,2015,7(12):35-36.
[5]赵丽媛,王建昌,李玉茜,等.75岁及以上冠心病心力衰竭患者用药规范化比较[J].中国老年学杂志,2017,37(02):356-358.
[6]张健,张宇辉.代表中国心力衰竭注册登记协作组多中心.前瞻性中国心力衰竭注册登记研究-病因、临床特点和治疗情况初步分析[J].中国循环杂志,2015,30(02):413-416.
[7]张琳.中西医结合治疗老年冠心病心力衰竭的临床观察[J/CD].中西医结合心血管病电子杂志,2017,5(13):173.
[8]朴正浩.探讨中西医结合治疗冠心病慢性心力衰竭的疗效[J/CD].中西医结合心血管病电子杂志,2015,3(32):42-43.
[9]史佃磊.中西医结合治疗冠心病慢性心力衰竭的疗效观察[J/CD].中西医结合心血管病电子杂志,2015,3(17):39-40.
[10]Kurtoglu GH,Catakoglu AB,Yildirimturk O,et al.Relationship between endothelial dysfunction and cardiovascular risk factors and the extent and severity of coronary artery disease[J].Turk Kardiyol Dern Ars,2014,42(05):435-443.
[11]王刚.中医辨证联合美托洛尔治疗冠心病心力衰竭的疗效分析[J].临床医药文献杂志,2016,3(11):2184-2185.
[12]赵书刚,李厚英,陈昕.补气畅络方治疗气虚血瘀型冠心病慢性心力衰竭的疗效观察及对炎症因子的影响[J].中西医结合心脑血管病杂志,2016,14(03):238-240.
[13]李琳,王燕,苏林,等.冠心病及心肌梗死后心力衰竭病人血管内皮功能障碍与中医证型的相关性研究[J].中西医结合心脑血管病杂志,2016,14(14):1569-1572.
[2]王文林,吴敏,赵艳花,等.两种中药注射剂辅助治疗冠心病心力衰竭的成本-效果分析[J].中国药房,2015,26(26):3614-3616.
[3]顾丽萍,胡菁,严蜀华.美托洛尔与曲美他嗪治疗老年冠心病心力衰竭的疗效及对患者心功能、心肌重塑和炎症因子的影响[J].中国老年学杂志,2017,37(01):89-91.
[4]黄孟军.中医辨证联合美托洛尔治疗冠心病心力衰竭的临床疗效分析[J].中医临床研究,2015,7(12):35-36.
[5]赵丽媛,王建昌,李玉茜,等.75岁及以上冠心病心力衰竭患者用药规范化比较[J].中国老年学杂志,2017,37(02):356-358.
[6]张健,张宇辉.代表中国心力衰竭注册登记协作组多中心.前瞻性中国心力衰竭注册登记研究-病因、临床特点和治疗情况初步分析[J].中国循环杂志,2015,30(02):413-416.
[7]张琳.中西医结合治疗老年冠心病心力衰竭的临床观察[J/CD].中西医结合心血管病电子杂志,2017,5(13):173.
[8]朴正浩.探讨中西医结合治疗冠心病慢性心力衰竭的疗效[J/CD].中西医结合心血管病电子杂志,2015,3(32):42-43.
[9]史佃磊.中西医结合治疗冠心病慢性心力衰竭的疗效观察[J/CD].中西医结合心血管病电子杂志,2015,3(17):39-40.
[10]Kurtoglu GH,Catakoglu AB,Yildirimturk O,et al.Relationship between endothelial dysfunction and cardiovascular risk factors and the extent and severity of coronary artery disease[J].Turk Kardiyol Dern Ars,2014,42(05):435-443.
[11]王刚.中医辨证联合美托洛尔治疗冠心病心力衰竭的疗效分析[J].临床医药文献杂志,2016,3(11):2184-2185.
[12]赵书刚,李厚英,陈昕.补气畅络方治疗气虚血瘀型冠心病慢性心力衰竭的疗效观察及对炎症因子的影响[J].中西医结合心脑血管病杂志,2016,14(03):238-240.
[13]李琳,王燕,苏林,等.冠心病及心肌梗死后心力衰竭病人血管内皮功能障碍与中医证型的相关性研究[J].中西医结合心脑血管病杂志,2016,14(14):1569-1572.